Relmada Therapeutics (RLMD) Total Current Liabilities (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Total Current Liabilities for 15 consecutive years, with $12.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 146.43% year-over-year to $12.9 million; the TTM figure through Mar 2026 stood at $12.9 million (up 146.43% YoY), while the FY2025 annual figure was $6.4 million, down 37.52% from the prior year.
• Total Current Liabilities grew to $12.9 million in Q1 2026 per RLMD's latest filing, from $6.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $20.8 million in Q3 2022 and bottomed at $5.1 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $10.8 million across 5 years, with a median of $10.3 million in 2024.
• Annual changes were most pronounced in 2023 — Total Current Liabilities plunged 59.46% — and 2026, when it soared 146.43%.
• Relmada Therapeutics' Total Current Liabilities stood at $12.5 million in 2022, then retreated by 2.2% to $12.2 million in 2023, then fell by 15.61% to $10.3 million in 2024, then plunged by 37.52% to $6.4 million in 2025, then jumped by 100.48% to $12.9 million in 2026.
• Business Quant data shows RLMD's Total Current Liabilities at $12.9 million in Q1 2026, $6.4 million in Q4 2025, and $5.2 million in Q3 2025.